Tine Wyseure

Tine Wyseure

Auto-generated profile, based on publicly available information

Tine Wyseure

Vividion Therapeutics, San Diego, California

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2018 in Blood
Verified
Journal Article
Open access
PDF file
TWTine Wyseure
Tine Wyseure
ECEsther J. Cooke
Esther J. Cooke
PDPaul Declerck
Paul Declerck
NBNiels Behrendt
Niels Behrendt
JMJoost C. M. Meijers
Joost C. M. Meijers
LMLaurent O. Mosnier
Laurent O. Mosnier
Joint bleeds are common in congenital hemophilia, but rare in acquired hemophilia A (aHA) for reasons unknown. To identify key mechanisms responsible for joint-specific bleeding in congenital hemophilia, bleeding phenotypes after joint injury and tail transection were compared in aHA wild-type mice (receiving an anti-FVIII antibody), and congenital hemophilia A (FVIII-/-) mice. Both aHA and FVIII-/- mice bled severely after tail transection, but consistent with clinical findings, joint bleeding was notably milder in aHA compared to FVIII-/- mice. Focus was directed to Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) to determine its potentially protective effect on joint bleeding in aHA. Joint bleeding in TAFI-/- mice with anti-FVIII antibody was increased, compared to wild-type aHA mice, and became indistinguishable from joint bleeding in FVIII-/- mice. Measurements of circulating TAFI zymogen consumption after joint injury indicated severely defective TAFI activation in FVIII-/- mice in vivo, consistent with previous in vitro analysis in FVIII-deficient plasma. In contrast, notable TAFI activation was observed in aHA mice, suggesting that TAFI protected aHA joints against bleeding. Pharmacological inhibitors of fibrinolysis revealed that urokinase Plasminogen Activator (uPA)-induced fibrinolysis drove joint bleeding, whereas tissue-type Plasminogen Activator (tPA)-mediated fibrinolysis contributed to tail bleeding. These data identify TAFI as an important modifier of hemophilic joint bleeding in aHA by inhibiting uPA-mediated fibrinolysis. Moreover, our data suggest that bleed protection by TAFI was absent in congenital FVIII-/- mice due to severely defective TAFI activation, underscoring the importance of clot protection in addition to clot formation when considering prohemostatic strategies for hemophilic joint bleeding. Key points The degree of TAFI activation in hemophilia A is a modifier of hemophilic joint bleeding that inversely affects bleeding severity. Defective TAFI activation in severe congenital hemophilia A impairs protection against uPA-mediated fibrinolysis in bleeding joints.

24 April 2026 in Cancer Discovery
Verified
Journal Article
Open access
NRNilotpal Roy
Nilotpal Roy
TWTine Wyseure
Tine Wyseure
ILI-Chung Lo
I-Chung Lo
JLJustine Lu
Justine Lu
CEChristie L. Eissler
Christie L. Eissler
MPMatthew P. Patricelli
Matthew P. Patricelli
The NRF2 transcription factor is constitutively active in cancer, in which it functions to maintain oxidative homeostasis and reprogram cellular metabolism. NRF2-active tumors exhibit NRF2 dependency and resistance to chemotherapy/radiotherapy (RT). In this study, we characterize VVD-065, a first-in-class NRF2 inhibitor that acts via an unprecedented allosteric molecular glue mechanism. In the absence of stress or mutation, NRF2 is rapidly degraded by the Kelch-like ECH-associated protein 1 (KEAP1)–cullin3 (CUL3) ubiquitin-ligase complex. VVD-065 specifically and covalently engages Cys151 on KEAP1, which in turn promotes KEAP1–CUL3 complex formation, leading to enhancement of NRF2 degradation. Previously reported Cys151-directed compounds decrease KEAP1–CUL3 interactions and stabilize NRF2, thus establishing KEAP1C151 as a tunable regulator of the KEAP1–CUL3 complex and NRF2 stability. VVD-065 inhibited NRF2-dependent tumor growth and sensitized cancers to chemotherapy/RT, supporting an open phase I clinical trial (NCT05954312). Significance: NRF2 hyperactivation is frequently observed in various solid tumors, including lung, esophageal, and head and neck cancers, highlighting NRF2 as a potential therapeutic target. We report a first-in-class KEAP1-dependent allosteric molecular glue degrader of NRF2, which demonstrated robust monotherapy responses in NRF2-activated cancers and effectively sensitized chemo-refractory tumors to chemotherapy. See related commentary by Hintzen and Burslem, p. XX

1 March 2024 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
ACAnne Costanzo
Anne Costanzo
DCDon Clarke
Don Clarke
MHMarie Holt
Marie Holt
SSSiddhartha Sharma
Siddhartha Sharma
KNKenna Nagy
Kenna Nagy
LTLuc Teyton
Luc Teyton
Type 1 diabetes (T1D) is a prototypic T cell–mediated autoimmune disease. Because the islets of Langerhans are insulated from blood vessels by a double basement membrane and lack detectable lymphatic drainage, interactions between endocrine and circulating T cells are not permitted. Thus, we hypothesized that initiation and progression of anti-islet immunity required islet neolymphangiogenesis to allow T cell access to the islet. Combining microscopy and single cell approaches, the timing of this phenomenon in mice was situated between 5 and 8 wk of age when activated anti-insulin CD4 T cells became detectable in peripheral blood while peri-islet pathology developed. This “peri-insulitis,” dominated by CD4 T cells, respected the islet basement membrane and was limited on the outside by lymphatic endothelial cells that gave it the attributes of a tertiary lymphoid structure. As in most tissues, lymphangiogenesis seemed to be secondary to local segmental endothelial inflammation at the collecting postcapillary venule. In addition to classic markers of inflammation such as CD29, V-CAM, and NOS, MHC class II molecules were expressed by nonhematopoietic cells in the same location both in mouse and human islets. This CD45− MHC class II+ cell population was capable of spontaneously presenting islet Ags to CD4 T cells. Altogether, these observations favor an alternative model for the initiation of T1D, outside of the islet, in which a vascular-associated cell appears to be an important MHC class II–expressing and –presenting cell.

17 June 2026
Verified
Other
Open access
NRNilotpal Roy
Nilotpal Roy
TWTine Wyseure
Tine Wyseure
ILI-Chung Lo
I-Chung Lo
JLJustine Lu
Justine Lu
CEChristie L. Eissler
Christie L. Eissler
MPMatthew P. Patricelli
Matthew P. Patricelli
Shows the anti-proliferative activity of VVD-065, observed across various cell lines and potentiated in 3D culture, is fundamentally linked to the presence of KEAP1 Cys151


17 June 2026
Verified
Other
Open access
PDF file
NRNilotpal Roy
Nilotpal Roy
TWTine Wyseure
Tine Wyseure
ILI-Chung Lo
I-Chung Lo
JLJustine Lu
Justine Lu
CEChristie L. Eissler
Christie L. Eissler
MPMatthew P. Patricelli
Matthew P. Patricelli
Shows synthesis routes of compounds